Recommendations for clinical biomarker specimen preservation and stability assessments

被引:24
作者
Dakappagari, Naveen [1 ]
Zhang, Hui [2 ]
Stephen, Laurie [3 ]
Amaravadi, Lakshmi [4 ]
Khan, Masood U. [5 ]
机构
[1] Navigate Biopharma Serv Inc, 1890 Rutherford Rd, Carlsbad, CA 92008 USA
[2] QPS LLC, 1 Innovat Way, Newark, DE USA
[3] Ampersand Biosci LLC, 3 Main St, Saranac Lake, NY USA
[4] Genzyme, 500 Kendall St Cambridge, Boston, MA USA
[5] Alliance Pharma, 17 Lee Blvd, Malvern, PA USA
关键词
biomarker preservation; biomarker specimen collection; biomarker stability; BLOOD COLLECTION; VALUES; PLASMA; INDEX; SERUM;
D O I
10.4155/bio-2017-0009
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
With the wide use of biomarkers to enable critical drug-development decisions, there is a growing concern from scientific community on the need for a 'standardized process' for ensuring biomarker specimen stability and hence, a strong desire to share best practices on preserving the integrity of biomarker specimens in clinical trials and the design of studies to evaluate analyte stability. By leveraging representative industry experience, we have attempted to provide an overview of critical aspects of biomarker specimen stability commonly encountered during clinical development, including: planning of clinical sample collection procedures, clinical site training, selection of sample preservation buffers, shipping logistics, fit-for-purpose stability assessments in the analytical laboratory and presentation of case studies covering widely utilized biomarker specimen types.
引用
收藏
页码:643 / 653
页数:11
相关论文
共 19 条
  • [1] [Anonymous], 2013, GUIDANCE IND DRAFT B
  • [2] Human Biospecimen Research: Experimental Protocol and Quality Control Tools
    Betsou, Fotini
    Barnes, Rebecca
    Burke, Thomas
    Coppola, Domenico
    DeSouza, Yvonne
    Eliason, James
    Glazer, Barbara
    Horsfall, David
    Kleeberger, Cynthia
    Lehmann, Sylvain
    Prasad, Anil
    Skubitz, Amy
    Somiari, Stella
    Guntell, Elaine
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (04) : 1017 - 1025
  • [3] Carroll TA, 2003, ANN CLIN LAB SCI, V33, P113
  • [4] Stability of immunophenotypic markers in fixed peripheral blood for extended analysis using flow cytometry
    Davis, Cuc
    Wu, Xiaoying
    Li, Weimin
    Fan, Hongtao
    Reddy, Manjula
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2011, 363 (02) : 158 - 165
  • [5] Dennis J. Ernst, 2007, PROCEDURES COLLECTIO, V27, P56
  • [6] DOUMAS BT, 1989, CLIN CHEM, V35, P151
  • [7] Biological sample collection and processing for molecular epidemiological studies
    Holland, NT
    Smith, MT
    Eskenazi, B
    Bastaki, M
    [J]. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2003, 543 (03) : 217 - 234
  • [8] Fit-for-purpose method development and validation for successful biomarker measurement
    Lee, JW
    Devanarayan, V
    Barrett, YC
    Weiner, R
    Allinson, J
    Fountain, S
    Keller, S
    Weinryb, I
    Green, M
    Duan, L
    Rogers, JA
    Millham, R
    O'Brien, PJ
    Sailstad, J
    Khan, M
    Ray, C
    Wagner, JA
    [J]. PHARMACEUTICAL RESEARCH, 2006, 23 (02) : 312 - 328
  • [9] A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue
    Neumeister, Veronique M.
    Parisi, Fabio
    England, Allison M.
    Siddiqui, Summar
    Anagnostou, Valsamo
    Zarrella, Elizabeth
    Vassilakopolou, Maria
    Bai, Yalai
    Saylor, Sasha
    Sapino, Anna
    Kluger, Yuval
    Hicks, David G.
    Bussolati, Gianni
    Kwei, Stephanie
    Rimm, David L.
    [J]. LABORATORY INVESTIGATION, 2014, 94 (04) : 467 - 474
  • [10] Evidence for Endotoxin Contamination in Plastic Na+-Heparin Blood Collection Tube Lots
    Newhall, Kathryn J.
    Diemer, Geoffrey S.
    Leshinsky, Natalia
    Kerkof, Keith
    Chute, Hilary T.
    Russell, Chris B.
    Rees, William
    Welcher, Andrew A.
    Patterson, Scott D.
    Means, Gary D.
    [J]. CLINICAL CHEMISTRY, 2010, 56 (09) : 1483 - 1491